: BRANDWOOD BIOMEDICAL

BRANDWOOD : BIOMEDICAL
Suite 408, 460 Pacific Hwy St Leonards
NSW 2065 Australia
securing your compliance
Office:
Fax:
+61 (0) 2 9906 2984
+61 (0) 2 8580 4613
[email protected]
SAMPLE AGENDAS
These are example agendas only. Please contact us to discuss your specific needs so we can tailor a
program for you.
Introduction to Medical Device Regulations in
Australia








Introduction
Legislative framework
Technical standards and documentation
Regulatory guidance
Review processes, fees and timelines
Manufacturing controls
Forthcoming changes
Case studies
Introduction to Medical Device Regulations in
China







Legislative framework
Technical standards and documentation
Regulatory guidance
Review processes, fees and timelines
Manufacturing controls
Forthcoming changes
Case studies
ISO 14971 Risk Management






Introduction to ISO 14971 Standard for Risk
Management
Design Risk Assessment
Production Risk Assessment
The Z Annexes and relationship to Directives –
matches and mismatches
Related Risk Analysis Standards
(FTA/FMEA/HAZOP/HACCP etc.)
Special Cases –ISO 10993, ISO 22442, IEC 62304
IEC 60601 Electrical Safety





Application of ISO 14971
Requirement in the TRF
Global Regulatory adoption and local variations
Software IEC 62304 and Software Level of
Concern
ISO 10993 and ISO TR 15499 – biological safety in
a risk management framework
Brandwood Biomedical
Biocompatibility Evaluation using ISO 10993
A Risk management model for efficient testing programs
The 2009 revision of ISO 10993 introduced a risk
management model which provides a rigorous approach to
biocompatibility evaluation, The old “tick list” approach
was replaced with a framework which emphasises
materials characterisation and targeting testing on the key
biological risks, avoiding unnecessary testing. This can cut
months from development programs and regulatory
approvals and save substantial costs.









ISO 10993 part 1 evaluation requirements and
the ISO TR 15499 Risk management model
Additional requirements of US FDA (including the
G95-1 Blue Book Memo and the 2013 Draft
Biocompatibility guidance.
Materials characterisation
Reducing regulatory and testing risk by smart
materials selection
Consideration of processing aids and additives
such as pigments
Selection of testing protocols
Special cases e.g. mucosal contact testing,
specific tissue exposures
How to determine limits for leachables (ISO
10993 part 17).
Determination of thresholds of toxicological
concern to determine safety of low level
unknown contaminants
Medical Device software







Medical software design controls
Application of IEC 62304 & IEC 62366
US & European software guidance
Verification a& Validation
Standalone software
Mobile apps
Product approval requirements in major markets
Page | 2